Spero Therapeutics Announces Positive Results from Phase 3 ADAPT-PO Trial of Oral Tebipenem HBr in Complicated Urinary Tract Infection and Acute Pyelonephritis

Spero Therapeutics announced positive topline results from ADAPT-PO, a pivotal Phase 3 clinical trial evaluating Spero’s oral antibiotic candidate, tebipenem HBr, for the treatment of adults with complicated urinary tract infection (cUTI) and acute pyelonephritis...

Pin It on Pinterest